← Back to Search

SER-109 for Clostridium Difficile Infection (ECOSPORIII Trial)

Phase 3
Waitlist Available
Research Sponsored by Seres Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4, 12 and 24 weeks after treatment
Awards & highlights
Pivotal Trial

Summary

Subjects will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days in Treatment Group I or matching placebo once daily for 3 consecutive days in Treatment Group II. The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI as determined by a toxin assay in adults up to 8 weeks after initiation of treatment.

Eligible Conditions
  • Clostridium Difficile Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4, 12 and 24 weeks after treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4, 12 and 24 weeks after treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Recurrence of CDI up to 8 Weeks
Secondary study objectives
Recurrence of CDI up to 4, 12 and 24 Weeks

Side effects data

From 2022 Phase 3 trial • 263 Patients • NCT03183141
34%
Diarrhea
14%
Flatulence
10%
Nausea
10%
Abdominal pain
3%
Urosepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort 1
Cohort 2

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SER-109Experimental Treatment1 Intervention
Received oral dose of SER-109
Group II: PlaceboPlacebo Group1 Intervention
Received matching placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SER-109
2015
Completed Phase 3
~540

Find a Location

Who is running the clinical trial?

Seres Therapeutics, Inc.Lead Sponsor
8 Previous Clinical Trials
783 Total Patients Enrolled
Lisa von Moltke, MDStudy DirectorSeres Therapeutics, Inc.
1 Previous Clinical Trials
203 Total Patients Enrolled
~22 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top